StockData

Starling Oncology vs Teladoc Health

STLN and TDOC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How STLN and TDOC compare

Teladoc Health is the larger company, worth 4.4 times as much as Starling Oncology ($1.6B against $361M).

Starling Oncology grew revenue faster over the last twelve months (34.6% versus −2.4% for Teladoc Health).

Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −5.7% compared with −6.3% at Teladoc Health.

Starling Oncology scores higher on the StockData Score (7 against 4 for Teladoc Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSTLNTDOC
Size and price
Market cap$361M$1.6B
Share price$3.54$8.70
Change, 1 year14.9%23.1%
Change, 5 years−47.2%−92.1%
Beta (5Y)2.331.25
Employees6415,600
StockData Score
Total score7 (better)4
Valuation score13 (better)
Growth score3 (better)0
Performance score11
Health score2 (better)0
Dividend score00
Valuation
P/S0.6× (better)0.6×
P/B–1.2×
P/FCF19.2×6.1× (better)
FCF yield5.2%16.5% (better)
Fair value–$14.83
Margin of safety–41.3%
Growth
Revenue growth (TTM)34.6% (better)−2.4%
Revenue growth, 5Y average21.8% (better)18.3%
Profitability
Gross margin–68.6%
Operating margin−3.4% (better)−6.6%
Net margin−5.7% (better)−6.3%
FCF margin3.0%10.6% (better)
Return on equity–−11.5%
Return on invested capital−96.2%−23.2% (better)
Financial health
Interest coverage−2.0× (better)−8.0×
Current ratio1.11 (better)0.87
Altman Z-score1.75 (better)−7.10
Piotroski F-score36 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions43.4%83.6%
Held by insiders56.6%0.71%
Insider net buying, 12 months−$11.1M−$2.7M (better)
Short interest, % of float–17.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.